Psychedelics in Multiple Sclerosis: Mechanisms, Challenges, and Prospects for Neuroimmune Modulation and Repair
Cells · 2025
DOI: 10.3390/cells14231872 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2025. Verfasst von Ivan Anchesi und 8 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Centro Neurolesi "Bonino-Pulejo", Via Provinciale Palermo, Contrada Casazza, 98124 Messina, Italy. Hauptthemen laut MEDLINE: Multiple Sclerosis, Hallucinogens, Neuroimmunomodulation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 171 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute, Ministry of Health, Italy.
Abstract (Originalsprache)
Multiple Sclerosis (MS) therapies effectively modulate peripheral immune responses but largely fail to promote neural repair within the central nervous system. This review evaluates whether psychedelic compounds (PSYs), via 5-HT2A activation, can fill a critical therapeutic gap: the need for agents that simultaneously suppress neuroinflammation and promote regeneration. We dissect the evidence suggesting PSYs can reprogram the neuroimmune milieu by downregulating key pro-inflammatory cytokines (e.g., TNF-α, IL-6) in glial cells while concurrently upregulating crucial neurotrophic factors (e.g., BDNF) that promote synaptic plasticity and oligodendrocyte support. However, we argue that the current evidence, largely derived from non-specific inflammation models, is insufficient to predict clinical efficacy in an autoimmune disease like MS. We critically analyze the significant translational barriers—from cardiovascular and psychiatric risks to profound legal and ethical challenges—that temper the immediate clinical promise. Finally, we propose a forward-looking perspective, suggesting that the true value of PSYs may lie not in their direct clinical use, but in uncovering novel therapeutic pathways. The emergence of non-hallucinogenic, functionally selective 5-HT2A agonists, inspired by psychedelic pharmacology, represents a more viable strategy to harness these mechanisms for MS therapy, demanding rigorous preclinical validation in disease-relevant models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IRCCS Centro Neurolesi "Bonino-Pulejo", Via Provinciale Palermo, Contrada Casazza, 98124 Messina, Italy.
- Department of Biomedical and Dental Sciences and Morpho Functional Imaging, University of Messina, 98125 Messina, Italy.
- Department of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy.
ORCID-Profile: Ivan Anchesi, Maria Francesca Astorino, Ivana Raffaele, Serena Silvestro, Aurelio Minuti, Marco Calabrò, Michele Scuruchi, Giovanni Luca Cipriano
Förderung
- Ministero della Salute
- Ministry of Health, Italy
Zitieren
APA
Anchesi, I., Astorino, M. F., Raffaele, I., Donato, D. S., Silvestro, S., Minuti, A., Calabrò, M., Scuruchi, M., & Cipriano, G. L. (2025). Psychedelics in Multiple Sclerosis: Mechanisms, Challenges, and Prospects for Neuroimmune Modulation and Repair. Cells. https://doi.org/10.3390/cells14231872
Vancouver
Anchesi I, Astorino MF, Raffaele I, Donato DS, Silvestro S, Minuti A, et al. Psychedelics in Multiple Sclerosis: Mechanisms, Challenges, and Prospects for Neuroimmune Modulation and Repair. Cells. 2025. doi:10.3390/cells14231872
BibTeX
@article{Anchesi2025,
author = {Anchesi, Ivan and Astorino, Maria Francesca and Raffaele, Ivana and Donato, Deborah Stefania and Silvestro, Serena and Minuti, Aurelio and Calabrò, Marco and Scuruchi, Michele and Cipriano, Giovanni Luca},
title = {Psychedelics in Multiple Sclerosis: Mechanisms, Challenges, and Prospects for Neuroimmune Modulation and Repair},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14231872}
}
EUVIMED